Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
Chronic Phase Chronic Myeloid Leukemia
Accelerated Phase Chronic Myeloid Leukemia
Blastic Phase Chronic Myeloid Leukemia
Philadelphia Positive Acute Lymphoblastic Leukemia
Resistant to Tyrosine Kinase Inhibitor Therapy
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A PHASE I/II, MULTI-CENTRE, TRIAL OF RUXOLITINIB THERAPY IN COMBINATION WITH NILOTINIB IN PATIENTS WITH PHILADELPHIA POSITIVE CHRONIC MYELOID LEUKEMIA OR ACUTE LYMPHOBLASTIC LEUKEMIA WHO HAVE FAILED TYROSINE KINASE INHIBITOR THERAPY|
- Phase I: Maximum Tolerated Dose (MTD) [ Time Frame: Average of 6 months ] [ Designated as safety issue: Yes ]Maximum Tolerated Dose (MTD) of Ruxolitinib with fixed dose of Nilotinib. Dose escalation will follow a 3+3 study design. The CTCAE v4.03 criteria will be used. Grade 4 toxicity will be accounted as dose limiting toxicity (DLT).
- Phase II: Major cytogenetic response [ Time Frame: Average of 6 months ] [ Designated as safety issue: No ]Major cytogenetic response defined by 35% or less of Philadelphia chromosomes by metaphase cytogenetics in marrow from CML and ALL patients
- Phase I: complete hematologic response [ Time Frame: Average of 3 months ] [ Designated as safety issue: No ]Complete hematologic response defined by CBC differential without any evidence of leukemia. It will be evaluated in CML patients in AP or BP, and patients with Ph+ ALL.
- Phase I: major cytogenetic response [ Time Frame: Average of 6 months ] [ Designated as safety issue: No ]Major cytogenetic response defined by 35% or less of Philadelphia chromosomes by metaphase cytogenetics in marrow taken at 6 months.
- Phase I: Safety and tolerability [ Time Frame: Average of 6 months ] [ Designated as safety issue: Yes ]It will be defined by NCI Common Terminology Criteria for Adverse Events (CTCAE)version 4.03 for adverse event reporting.
- Phase II: complete hematologic response [ Time Frame: Average of 3 months ] [ Designated as safety issue: No ]Complete hematologic response defined by CBC differential without any evidence of leukemia. It will be evaluated in the CML patients in AP or BP and in patients with Ph+ ALL.
- Phase II (exploratory): pharmacokinetic profile of combination of Nilotinib with Ruxolitinib [ Time Frame: During first 24 hours of first dose ] [ Designated as safety issue: No ]Cmax will be measured for the maximum plasma concentration of nilotinib after oral administration.
|Study Start Date:||August 2013|
|Estimated Study Completion Date:||July 2016|
|Estimated Primary Completion Date:||July 2016 (Final data collection date for primary outcome measure)|
Experimental: Nilotinib with Ruxolitinib
Nilotinib: Given that recommended dose of Nilotinib for imatinib failed CML patients is 400mg twice daily, Nilotinib dose will remain fixed at 400mg bid throughout the cycles.
Ruxolitinib: In the phase I part of the study, dose escalation will follow a 3+3 study design. Dose modifications will not occur, as the purpose of this study is to determine the maximum tolerated dose. Ruxolitinib will be given at one of 3 fixed dose levels for the duration of their treatment, either 10mg twice daily, 15mg twice daily or 20mg twice daily.
Nilotinib dose will remain fixed at 400mg bid throughout the cycles. BCR-ABL kinase inhibitor
Other Name: TasignaDrug: Ruxolitinib
In the phase I part of the study, dose escalation will follow a 3+3 study design at either of 3 fixed dose levels (10 mg bid, 15 mg bid or 20 mg bid).
No intra-patient dose-escalation will occur. JAK inhibitor
The purpose of this study is to find out if multiple tyrosine kinase inhibitor resistant chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL) can be treated with combination approach of Nilotinib with Ruxolitinib which may block alternative pathway besides BCR-ABL kinase inhibition in Ph positive leukemia, esp against JAK2-STAT5 pathway. First step is to define the dose of Ruxolitinib with fixed dose of Nilotinib which had been approved at the dose of 400mg bid for imatinib failed CML.
During phase I part of the study,dose escalations will be decided on the basis of DLTs observed hence the exact sample size could not be predicted with certainty but will range between 9-12 patients. Three patients will be enrolled per dose level. Accordingly 9 patients are expected to be enrolled. If a DLT is observed, 3 more patients will be enrolled at the dose level in which the DLT occurred.
The study will be conducted at multiple sites across Canada and enrollment will be competitive. Once 3 patients are enrolled in a cohort, that dose level will be closed to enrollment until safety assessment of the 3 subjects is performed at the end of cycle 1. This procedure will be performed for each dosing cohort. Patients will be assigned to a dose level based on authorization from the sponsor in collaboration with Ozmosis Research Inc.
For the phase II part of the study, once the RPTD has been established in the phase I portion of this trial, the phase II will begin. The phase II portion will be a two-stage, single arm, unblinded study investigating the potential efficacy of the combination of Ruxolitinib and Nilotinib.
A maximum of 20 patients will be accrued in the phase II portion. Those patients treated in the phase I portion of this trial at the RPTD will be included in the analysis of the Phase II study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01914484
|Contact: Sima Bogomilsky, RN BScN CON(C)||firstname.lastname@example.org|
|Contact: Dennis Kim, MD/PhD||416-946-4501 ext email@example.com|
|Princess Margaret Hospital / University Health Network||Recruiting|
|Toronto, Ontario, Canada, M5G 2M9|
|Contact: Sima Bogomilsky, RN BScN CON(C) 416-946-4646 firstname.lastname@example.org|
|Contact: Sonal Malhotra, M.Sc., Ph.D,CCRP 416-946-4501 ext 3449 email@example.com|
|Principal Investigator: Dennis Kim, MD/PhD|
|Sub-Investigator: Jeffrey H Lipton, MD/PhD|
|Principal Investigator:||Dennis Kim, MD/PhD||Princess Margaret Hospital, Canada|